JenaValve Technology Acquisition, Valuation, Funding & Investors

AcuityMD is a software platform that aggregates clinical utilization data to accelerate medical device commercialization for orthopedics and spine companies. Boston-headquartered, it analyzes procedure volumes and surgeon preferences from electronic health records across U.S. hospitals. The platform equips sales teams with market intelligence on over 10 million procedures, enabling targeted account planning and evidence-based launches.

Synchron is a neurotechnology company advancing brain-computer interfaces through its endovascular Stentrode device. Delivered via catheter to the brain's blood vessels, it records neural signals for controlling external devices like prosthetics and computers. Brooklyn-headquartered, Synchron conducts clinical trials in Australia and the United States targeting paralysis patients.

BenevolentAI is a London-headquartered clinical-stage company using artificial intelligence for drug discovery, listed on Euronext Amsterdam under BAI. Its platform supports 13 named programs and over 10 exploratory ones, with collaborations including AstraZeneca on respiratory and cardiovascular diseases. Facilities in Cambridge and New York enable wet-lab validation of AI-generated candidates.

Cornerstone Robotics is a Shenzhen-based developer of surgical robots enhancing minimally invasive procedures in Chinese hospitals. The company produces the Toumai system for laparoscopic surgeries, approved by NMPA for colorectal and urology applications. Cornerstone Robotics partners with tertiary hospitals in Beijing and Shanghai for clinical trials and deployments.

Dental Monitoring is a Paris-headquartered teledentistry company founded in 2014 offering AI-powered remote monitoring for orthodontic treatments. Its app enables patients to scan teeth via smartphone, analyzed by algorithms for 200-plus clinical criteria. The firm employs over 400 staff across Europe, the United States, Australia, Hong Kong, and Singapore, serving 3 million patients globally.

OrCam Technologies is a Tel Aviv-based developer of wearable visual aid devices. The OrCam MyEye 2.0 clips onto eyeglasses and reads text aloud, recognizes faces, identifies products, and detects colors via AI-powered camera. Founded in 2010, the company serves people with vision impairment, dyslexia, and reading difficulties. OrCam partners with retailers like Boots and distributes globally.

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.

Scivita Medical Technology is a medical device manufacturer specializing in advanced endoscopy systems for minimally invasive diagnostics and surgery. Its portfolio includes 4K ultra-high-definition endoscopes, 3D visualization platforms, narrow-band imaging for fluorescence, and single-use disposable scopes covering flexible and rigid formats. Headquartered in Hangzhou, China, the firm holds certifications from China's NMPA and exports to over 50 countries. Scivita supplies products to hospitals in gastroenterology, urology, and ENT fields, with notable deployments in Asia-Pacific surgical centers.

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Huihe Healthcare is a Shanghai-headquartered medical device company established in 2019. The firm specializes in innovative devices addressing structural heart diseases, including transcatheter solutions for mitral and tricuspid valve repair.

Umoja Biopharma engineers in vivo CAR T-cell therapies that reprogram patients' T cells to attack solid tumors and hematological malignancies resistant to existing treatments. Seattle-headquartered, the company advances its AlloVector platform for localized immune cell activation without ex vivo manipulation. Partnerships with Biogen and Takeda support clinical progression in oncology pipelines targeting glioblastoma and other cancers.

SEEGENE Inc is engaged in the healthcare sector. The Korean firm specializes in developing upgraded technology for accurate diagnosis of various diseases. Its products include pathogen inspection solutions such as respiratory, gastrointestinal, tuberculosis and meningitis pathogens.

RefleXion Medical is a developer of biology-guided radiotherapy systems for cancer treatment. Hayward-headquartered in California, RefleXion's X1 machine delivers stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT platform uses real-time PET imaging to target metastatic tumors with subsecond precision. RefleXion raised over $380 million in funding from investors including Sofinnova and Temasek.

LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.

FibroGen is a biopharmaceutical company discovering therapies based on hypoxia-inducible factor and connective tissue growth factor biology for anemia, fibrosis, and cancer. Its flagship product roxadustat, a HIF-PH inhibitor, received approval in China in 2018 and Japan in 2019 for anemia in chronic kidney disease, with ongoing global trials. Headquartered in San Francisco, California, FibroGen partners with AstraZeneca and Astellas for commercialization in multiple regions.